LEXX Stock Analysis
LE
Uncovered
Lexaria Bioscience Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm is a global innovator in drug delivery platforms. The firm operates through two segments: Intellectual Property and Products. The Company’s patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting oral delivery. The Company’s operations involve the development and usage, including licensing, of its DehydraTECH Technology. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with approximately 27 patents granted and roughly 50 patents pending worldwide. The Company’s subsidiaries include Lexaria CanPharm ULC, Lexaria CanPharm Holdings Corp., PoViva Corp., Lexaria Hemp Corp., Kelowna Management Services Corp., Lexaria Nicotine LLC and Lexaria Pharmaceutical Corp.